TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin
In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Limited cross-variant immunity without vaccination (Nature) EUA for boosters in 5-11 year olds (FDA) Stages of COVID-19 (AIDS Rev) B.1.1.529 attack rate in Australia (JID) Sce...
Source: This Week in Virology - MP3 Edition - May 21, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Talk Evidence covid-19 update - drop in excess deaths, HIV drugs, academic promotion
In this week's Talk Evidence we're hearing about how the death rate has dropped below average, disappointment about HIV drugs for covid-19 treatment, a trial to reduce polypharmacy, and why academic promotions matter to everyone else.
1.35 - Carl gives us one of his death updates
3.30 - Helen asks if it’s finally time to be able to do the international comparisons we’ve been waiting for?
16.10 - New research suggests that extreme PPE prevents transmission - but PPE came with a whole range of other viral suppression measur es, and they all work together.
21.30 - The Recovery trial has said that lopinavir-ritonavi...
Source: The BMJ Podcast - July 3, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Talk Evidence covid-19 update - drop in excess deaths, HIV drugs, academic promotion
In this week's Talk Evidence we're hearing about how the death rate has dropped below average, disappointment about HIV drugs for covid-19 treatment, a trial to reduce polypharmacy, and why academic promotions matter to everyone else.
1.35 - Carl gives us one of his death updates
3.30 - Helen asks if it’s finally time to be able to do the international comparisons we’ve been waiting for?
16.10 - New research suggests that extreme PPE prevents transmission - but PPE came with a whole range of other viral suppression measures, and they all work together.
21.30 - The Recovery trial has said that lopinavir-ritonavir ...
Source: The BMJ Podcast - July 3, 2020 Category: General Medicine Authors: BMJ Group Source Type: podcasts
Dolutegravir vs Darunavir: Positive Data From FLAMINGO
Dr. Paul Sax discusses results of the FLAMINGO study comparing dolutegravir vs ritonavir-boosted darunavir in treatment-naive patients with HIV. (Source: Medscape HIV AIDS Podcast)
Source: Medscape HIV AIDS Podcast - September 26, 2013 Category: Infectious Diseases Authors: Medscape Source Type: podcasts
